Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D

Sponsor
Nanexa AB
Study ID
NCT06439056
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose with the study is to assess pharmacokinetics of NEX-22A in patients with type 2 diabetes.

Key Dates

Start date
May 27, 2024
Status verified
Sep 2025
Primary completion
Jul 18, 2025
Completion
Jul 18, 2025

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single dose of NEX-22-01
    The trial is single ascending dose study where the dose is escalated depending on previous cohorts PK data.

Primary Outcome Measure

To evaluate the PK profile of liraglutide after single ascending doses of NEX-22A in subjects with stable type 2 diabetes [ Time Frame: From administration of study drug until 36 days ]

Related Studies